Recombinant factor IX
| Names | |
|---|---|
| Trade names | Benefix, Rixubis,[1] Ixinity, Alprolix Idelvion, Rebinyn, others |
| Other names | Coagulation factor IX; recombinant factor IX; nonacog alfa; albutrepenonacog alfa; eftrenonacog alfa; nonacog beta pegol |
| Clinical data | |
| Main uses | Haemophilia B[1] |
| Side effects | Fever, cough, pain at the site of injection, nausea, allergic reactions[2][3] |
| External links | |
| AHFS/Drugs.com | Monograph |
Recombinant factor IX, also known as nonacog alfa among others, is a medication used to treat haemophilia B.[1] Specifically it is used to treat and prevent bleeding.[1] Its use improves quality of life.[1] It is given by slow injection into a vein.[1]
Common side effects include fever, cough, pain at the site of injection, and nausea.[2] It may also result in allergic reactions including angioedema, hives, wheezing, or low blood pressure.[3] Antibodies that block its ability to work may also develop.[3] It is a manufactured version of the blood clotting enzyme factor IX, made by recombinant methods.[1]
Recombinant versions were approved for medical use in the United States and Europe in 1997.[2][3][4] It is on the World Health Organization's List of Essential Medicines.[5] In the United Kingdom 1,000 units costs the NHS about £600 as of 2023.[6] This amount in the United States costs about 1,600 USD.[7] There are also versions made from human plasma, but these are associated with risks of infection.[8][6][4]
Types
Recombinant factor IX formulations include:
- nonacog alfa (brand name BeneFix)[3]
- albutrepenonacog alfa (brand name Idelvion)[9]
- eftrenonacog alfa (brand name Alprolix)[10]
- nonacog beta pegol (brand name Refixia)[11]
History
Factor IX concentrates were developed from human plasma in the late 1960s.[4] Recombinant versions came into medical use in 1997.[4] In the 1950s and 1960s fresh frozen plasma (FFP) was often used.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Factor IX (Recombinant) (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 September 2017. Retrieved 12 September 2023. Archived 24 September 2017 at the Wayback Machine
- ↑ 2.0 2.1 2.2 "BENEFIX (coagulation factor ix- recombinant kit". Dailymed. Archived from the original on 29 January 2023. Retrieved 12 September 2023. Archived 29 January 2023 at the Wayback Machine
- ↑ 3.0 3.1 3.2 3.3 3.4 "BeneFIX EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 17 June 2020. Retrieved 17 June 2020. Archived 17 June 2020 at the Wayback Machine
- ↑ 4.0 4.1 4.2 4.3 4.4 "Hemophilia: From Plasma to Recombinant Factors". 2008. Archived from the original on 29 May 2023. Retrieved 13 September 2023. Archived 29 May 2023 at the Wayback Machine
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ 6.0 6.1 "Factor IX fraction, dried [Specialist drug] Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 13 September 2023. Archived 13 September 2023 at the Wayback Machine
- ↑ "Benefix". GoodRx. Retrieved 13 September 2023.
- ↑ "Haemonine 500 / Haemonine 1000". EMC. Archived from the original on 11 April 2022. Retrieved 13 September 2023. Archived 11 April 2022 at the Wayback Machine
- ↑ "Idelvion EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 17 June 2020. Retrieved 17 June 2020. Archived 17 June 2020 at the Wayback Machine
- ↑ "Alprolix EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 August 2020. Retrieved 17 June 2020. Archived 11 August 2020 at the Wayback Machine
- ↑ "Refixia EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 18 June 2020. Retrieved 17 June 2020. Archived 18 June 2020 at the Wayback Machine
External links
- "Coagulation Factor IX (Recombinant), Fc Fusion Protein". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-11-22. Retrieved 2023-04-24. Archived 2022-11-22 at the Wayback Machine
- "Eftrenonacog alfa". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-11-22. Retrieved 2023-04-24. Archived 2022-11-22 at the Wayback Machine
- "Nonacog alfa". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-11-22. Retrieved 2023-04-24. Archived 2022-11-22 at the Wayback Machine
- "Albutrepenonacog alfa". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-11-22. Retrieved 2023-04-24. Archived 2022-11-22 at the Wayback Machine
- "Nonacog beta pegol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-11-22. Retrieved 2023-04-24. Archived 2022-11-22 at the Wayback Machine
- GeneReviews/NCBI/NIH/UW entry on Hemophilia B Archived 2019-10-20 at the Wayback Machine
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Coagulation system
- Pfizer brands
- Zymogens
- Sanofi
- World Health Organization essential medicines
- RTT